Switch theme
Sign up to access all valuation multiples
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.
2021
106
LTM Revenue $0.8M
Last FY EBITDA -$50.5M
$28.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Rani Therapeutics has a last 12-month revenue (LTM) of $0.8M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Rani Therapeutics achieved revenue of $1.0M and an EBITDA of -$50.5M.
Rani Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Rani Therapeutics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $0.8M | XXX | $1.0M | XXX | XXX | XXX |
| Gross Profit | $0.8M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$50.5M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -4915% | XXX | XXX | XXX |
| EBIT | -$51.8M | XXX | -$49.6M | XXX | XXX | XXX |
| EBIT Margin | -6836% | XXX | -4825% | XXX | XXX | XXX |
| Net Profit | -$29.3M | XXX | -$30.0M | XXX | XXX | XXX |
| Net Margin | -3860% | XXX | -2920% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $20.9M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Rani Therapeutics's stock price is $1.
Rani Therapeutics has current market cap of $18.8M, and EV of $28.6M.
See Rani Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $28.6M | $18.8M | XXX | XXX | XXX | XXX | $-1.00 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Rani Therapeutics has market cap of $18.8M and EV of $28.6M.
Rani Therapeutics's trades at 27.8x EV/Revenue multiple, and -0.6x EV/EBITDA.
Equity research analysts estimate Rani Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Rani Therapeutics has a P/E ratio of -0.6x.
See valuation multiples for Rani Therapeutics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $18.8M | XXX | $18.8M | XXX | XXX | XXX |
| EV (current) | $28.6M | XXX | $28.6M | XXX | XXX | XXX |
| EV/Revenue | 37.7x | XXX | 27.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -0.6x | XXX | XXX | XXX |
| EV/EBIT | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
| EV/Gross Profit | 37.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.6x | XXX | -0.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -0.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRani Therapeutics's last 12 month revenue growth is -70%
Rani Therapeutics's revenue per employee in the last FY averaged $10K, while opex per employee averaged $0.5M for the same period.
Rani Therapeutics's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Rani Therapeutics's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Rani Therapeutics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -70% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -4915% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | -4985% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $10K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2596% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 4925% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Rani Therapeutics acquired XXX companies to date.
Last acquisition by Rani Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Rani Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Rani Therapeutics founded? | Rani Therapeutics was founded in 2021. |
| Where is Rani Therapeutics headquartered? | Rani Therapeutics is headquartered in United States of America. |
| How many employees does Rani Therapeutics have? | As of today, Rani Therapeutics has 106 employees. |
| Who is the CEO of Rani Therapeutics? | Rani Therapeutics's CEO is Mr. Talat Imran. |
| Is Rani Therapeutics publicy listed? | Yes, Rani Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Rani Therapeutics? | Rani Therapeutics trades under RANI ticker. |
| When did Rani Therapeutics go public? | Rani Therapeutics went public in 2021. |
| Who are competitors of Rani Therapeutics? | Similar companies to Rani Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Rani Therapeutics? | Rani Therapeutics's current market cap is $18.8M |
| What is the current revenue of Rani Therapeutics? | Rani Therapeutics's last 12 months revenue is $0.8M. |
| What is the current revenue growth of Rani Therapeutics? | Rani Therapeutics revenue growth (NTM/LTM) is -70%. |
| What is the current EV/Revenue multiple of Rani Therapeutics? | Current revenue multiple of Rani Therapeutics is 37.7x. |
| Is Rani Therapeutics profitable? | Yes, Rani Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
